AAUM (Average Assets Under Management) of ₹171.56 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 52.6% | 53.3% | ▲ +0.7% |
| Healthcare Services | 16.7% | 16.2% | ▼ -0.5% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 53.3% | 53.5% | ▲ +0.2% |
| Healthcare Services | 16.2% | 15.3% | ▼ -0.9% |
Comparing Jul 2026 → Aug 2026
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Divi's Laboratories Limited ₹13.89 Cr |
Pharmaceuticals & Biotechnology | 6.07% | 6.96% | +0.89% |
| 2 | Glenmark Pharmaceuticals Limited ₹4.30 Cr |
Pharmaceuticals & Biotechnology | 1.99% | 2.15% | +0.16% |
| 3 | IPCA Laboratories Limited ₹3.38 Cr |
Pharmaceuticals & Biotechnology | 1.54% | 1.70% | +0.16% |
| 4 | Aurobindo Pharma Limited ₹5.51 Cr |
Pharmaceuticals & Biotechnology | 2.61% | 2.76% | +0.15% |
| 5 | Gland Pharma Limited ₹2.63 Cr |
Pharmaceuticals & Biotechnology | 1.17% | 1.32% | +0.15% |
| 6 | Laurus Labs Limited ₹8.25 Cr |
Pharmaceuticals & Biotechnology | 4.02% | 4.14% | +0.12% |
| 7 | GlaxoSmithKline Pharmaceuticals Limited ₹1.43 Cr |
Pharmaceuticals & Biotechnology | 0.64% | 0.72% | +0.08% |
| 8 | Anthem Biosciences Limited ₹95.51 L |
Pharmaceuticals & Biotechnology | 0.44% | 0.48% | +0.04% |
| 9 | Global Health Limited ₹1.47 Cr |
Healthcare Services | 0.71% | 0.73% | +0.02% |
| 10 | Zydus Lifesciences Limited ₹2.66 Cr |
Pharmaceuticals & Biotechnology | 1.32% | 1.33% | +0.01% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Lupin Limited ₹6.14 Cr |
Pharmaceuticals & Biotechnology | 3.48% | 3.08% | -0.40% |
| 2 | Max Healthcare Institute Limited ₹9.03 Cr |
Healthcare Services | 4.89% | 4.52% | -0.37% |
| 3 | Sun Pharmaceutical Industries Limited ₹21.94 Cr |
Pharmaceuticals & Biotechnology | 11.30% | 10.99% | -0.31% |
| 4 | Cipla Limited ₹8.74 Cr |
Pharmaceuticals & Biotechnology | 4.69% | 4.38% | -0.31% |
| 5 | Fortis Healthcare Limited ₹5.47 Cr |
Healthcare Services | 2.93% | 2.74% | -0.19% |
| 6 | Apollo Hospitals Enterprise Limited ₹11.00 Cr |
Healthcare Services | 5.69% | 5.51% | -0.18% |
| 7 | Torrent Pharmaceuticals Limited ₹8.88 Cr |
Pharmaceuticals & Biotechnology | 4.61% | 4.45% | -0.16% |
| 8 | Alkem Laboratories Limited ₹2.74 Cr |
Pharmaceuticals & Biotechnology | 1.52% | 1.37% | -0.15% |
| 9 | Aster DM Healthcare Limited ₹2.17 Cr |
Healthcare Services | 1.21% | 1.08% | -0.13% |
| 10 | Biocon Limited ₹3.28 Cr |
Pharmaceuticals & Biotechnology | 1.74% | 1.64% | -0.10% |
24 stocks — Aug 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹21.94 Cr |
Pharmaceuticals & Biotechnology |
10.99%
|
|
| 2 |
₹13.89 Cr |
Pharmaceuticals & Biotechnology |
6.96%
|
|
| 3 |
₹11.00 Cr |
Healthcare Services |
5.51%
|
|
| 4 |
₹9.03 Cr |
Healthcare Services |
4.52%
|
|
| 5 |
₹8.88 Cr |
Pharmaceuticals & Biotechnology |
4.45%
|
|
| 6 |
₹8.74 Cr |
Pharmaceuticals & Biotechnology |
4.38%
|
|
| 7 |
₹8.25 Cr |
Pharmaceuticals & Biotechnology |
4.14%
|
|
| 8 |
₹7.10 Cr |
Pharmaceuticals & Biotechnology |
3.56%
|
|
| 9 |
₹6.14 Cr |
Pharmaceuticals & Biotechnology |
3.08%
|
|
| 10 |
₹5.51 Cr |
Pharmaceuticals & Biotechnology |
2.76%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.